Work

A pediatric phase I study of larotrectinib, a highly selective inhibitor of the tropomyosin receptor kinase (TRK) family.

Year: 2017

Type: conference-abstract

Source: Journal of Clinical Oncology

DOI: 10.1200/jco.2017.35.15_suppl.10510

Authors: Theodore Willis Laetsch, Steven G. DuBois, Ramamoorthy Nagasubramanian, Brian Turpin, Leo Mascarenhas, Noah Federman, Mark Reynolds, Steven Smith, Scott Cruickshank, Michael Craig Cox, Alberto S. Pappo, Douglas S. Hawkins

Institutions: The University of Texas Southwestern Medical Center, Dana-Farber Cancer Institute, Dana-Farber/Boston Children's Cancer and Blood Disorders Center, Nemours Children's Clinic, Cincinnati Children's Hospital Medical Center, University of Southern California, Children's Hospital of Los Angeles, University of California, Los Angeles, St. Jude Children's Research Hospital, Seattle Children's Hospital, University of Washington, Fred Hutch Cancer Center

Language: English

Topic: Sarcoma Diagnosis and Treatment

Subfield: Pulmonary and Respiratory Medicine

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W2892333732

Cites:

Cited by: 12

Related to: 10